Pegylated liposomal formulation of doxorubicin overcomes drug resistance in a genetically engineered mouse model of breast cancer

Cancer statistics, 2012

Rebecca L. Siegel, Deepa Naishadham, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2012 · 10.7K citations · Full text

Medicine, Oncology, Cancer Epidemiology +16

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from <i>BRCA</i> Mutation Carriers

Peter C.C. Fong, David S. Boss, Timothy A. Yap et al. · New England Journal of Medicine · 2009 · 3.6K citations · Full text

Medicine, Oncology, Pharmacology +17

Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer

E O’Brien, Nely Wigler, Moshe Inbar et al. · Annals of Oncology · 2004 · 1.7K citations · Full text

Medicine, Oncology, Pharmacology +17

Openings between Defective Endothelial Cells Explain Tumor Vessel Leakiness

Hiroya Hashizume, Shunichi Morikawa, John W. McLean et al. · American Journal Of Pathology · 2000 · 1.7K citations · Full text

Medicine, Cell Biology, Oncology +10

Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer

Colin C. Pritchard, Joaquı́n Mateo, Michael F. Walsh et al. · New England Journal of Medicine · 2016 · 1.7K citations · Full text

Life Sciences, Genetics, Oncology +17